229 related articles for article (PubMed ID: 33797782)
1. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.
Rodrigues FB; Byrne LM; Lowe AJ; Tortelli R; Heins M; Flik G; Johnson EB; De Vita E; Scahill RI; Giorgini F; Wild EJ
J Neurochem; 2021 Jul; 158(2):539-553. PubMed ID: 33797782
[TBL] [Abstract][Full Text] [Related]
2. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
Front Immunol; 2022; 13():997240. PubMed ID: 36263032
[TBL] [Abstract][Full Text] [Related]
3. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease.
Ou ZA; Byrne LM; Rodrigues FB; Tortelli R; Johnson EB; Foiani MS; Arridge M; De Vita E; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
Sci Rep; 2021 Feb; 11(1):3481. PubMed ID: 33568689
[TBL] [Abstract][Full Text] [Related]
4. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
Chatterjee P; Zetterberg H; Goozee K; Lim CK; Jacobs KR; Ashton NJ; Hye A; Pedrini S; Sohrabi HR; Shah T; Asih PR; Dave P; Shen K; Taddei K; Lovejoy DB; Guillemin GJ; Blennow K; Martins RN
J Neuroinflammation; 2019 Oct; 16(1):186. PubMed ID: 31601232
[TBL] [Abstract][Full Text] [Related]
5. Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau.
Jacobs KR; Lim CK; Blennow K; Zetterberg H; Chatterjee P; Martins RN; Brew BJ; Guillemin GJ; Lovejoy DB
Neurobiol Aging; 2019 Aug; 80():11-20. PubMed ID: 31055163
[TBL] [Abstract][Full Text] [Related]
6. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan metabolism and oxidative stress in patients with Huntington's disease.
Stoy N; Mackay GM; Forrest CM; Christofides J; Egerton M; Stone TW; Darlington LG
J Neurochem; 2005 May; 93(3):611-23. PubMed ID: 15836620
[TBL] [Abstract][Full Text] [Related]
8. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington's disease.
Lowe AJ; Rodrigues FB; Arridge M; De Vita E; Johnson EB; Scahill RI; Byrne LM; Tortelli R; Heslegrave A; Zetterberg H; Wild EJ
Brain Commun; 2022; 4(6):fcac258. PubMed ID: 36382217
[TBL] [Abstract][Full Text] [Related]
10. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
[TBL] [Abstract][Full Text] [Related]
11. Development of a translational inflammation panel for the quantification of cerebrospinal fluid Pterin, Tryptophan-Kynurenine and Nitric oxide pathway metabolites.
Yan J; Han VX; Heng B; Guillemin GJ; Bandodkar S; Dale RC
EBioMedicine; 2022 Mar; 77():103917. PubMed ID: 35279631
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.
Rodrigues FB; Byrne L; McColgan P; Robertson N; Tabrizi SJ; Leavitt BR; Zetterberg H; Wild EJ
J Neurochem; 2016 Oct; 139(1):22-5. PubMed ID: 27344050
[TBL] [Abstract][Full Text] [Related]
13. Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington's disease.
van de Zande NA; Bulk M; Najac C; van der Weerd L; de Bresser J; Lewerenz J; Ronen I; de Bot ST
Neuroimage Clin; 2023; 39():103450. PubMed ID: 37327706
[TBL] [Abstract][Full Text] [Related]
14. Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects.
Herman S; Niemelä V; Emami Khoonsari P; Sundblom J; Burman J; Landtblom AM; Spjuth O; Nyholm D; Kultima K
Sci Rep; 2019 Mar; 9(1):4129. PubMed ID: 30858393
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.
Lowe AJ; Sjödin S; Rodrigues FB; Byrne LM; Blennow K; Tortelli R; Zetterberg H; Wild EJ
PLoS One; 2020; 15(8):e0233820. PubMed ID: 32804976
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
[TBL] [Abstract][Full Text] [Related]
17. Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis.
Alarcan H; Chaumond R; Emond P; Benz-De Bretagne I; Lefèvre A; Bakkouche SE; Veyrat-Durebex C; Vourc'h P; Andres C; Corcia P; Blasco H
Biomolecules; 2021 May; 11(5):. PubMed ID: 34063031
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid Biomarkers for Huntington's Disease.
Byrne LM; Wild EJ
J Huntingtons Dis; 2016; 5(1):1-13. PubMed ID: 27031730
[TBL] [Abstract][Full Text] [Related]
19. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.
Aeinehband S; Brenner P; Ståhl S; Bhat M; Fidock MD; Khademi M; Olsson T; Engberg G; Jokinen J; Erhardt S; Piehl F
Brain Behav Immun; 2016 Jan; 51():47-55. PubMed ID: 26189678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
